A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors Clinical Trial

Official title:

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated， Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05459844
• Other study ID #: XT-XTR008-3-01
• Status: Recruiting
• Phase: Phase 3
• Start date: August 31, 2022
• Est. completion date: December 2028

Study information

• Verified date: February 2023
• Source: Sinotau Pharmaceutical Group
• Contact: Shan Zhang
• Phone: 010-52805710
• Email: zhangshan[@]sinotau.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium[177Lu] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

Description:

After the screening period, participants who signed the ICF and were eligible for the study in accordance with the entry criteria were randomly assigned to treatment either Lutetium[177Lu] Oxodotreotide Injection or Octreotide LAR. Participant randomization was performed according to a centralized permuted block randomization scheme with a balanced ratio (1:1) between the 2 treatment groups, stratified by primary site of tumor (pancreatic or non-pancreatic), NET pathological grading (G1 or G2) and by the length of time that a participant was on a constant dose of Octreotide (=< 6 versus > 6 months). Objective tumor assessment in both groups was performed every 12+/-1 weeks from the randomization date according to RECIST Criteria until progression was centrally confirmed: any participants with progressive disease ceased the treatment/assessment period and proceeded to the long-term follow-up period for evaluation of survival and long-term safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 196
• Est. completion date: December 2028
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent document.

2. Aged 18 years or older.

3. Histopathologically confirmed low and moderate grade (G1 or G2) unresectable locally advanced or metastatic GEP-NET (based on the fifth edition of the WHO classification and grading criteria for neuroendocrine tumors of the digestive system in 2019, to be centrally confirmed).

4. Prior treatment of advanced NET with = 2 lines of systemic antitumor regimen, which must include a fixed dose of Octreotide LAR (20-30 mg/3-4 weeks) for at least 12 weeks of continuous treatment with disease progression.

5. Presence of disease progression prior to randomization (time point of disease progression limited to 1 year prior to randomization and no other antitumor therapy received after progression).

6. Presence of at least 1 measurable site of disease (based on RECIST 1.1).

7. All target lesions (based on RECIST 1.1) at baseline must be confirmed as growth inhibitor receptor positive by 68Ga-Dotatate PET/CT (all based on BIRC assessment results).

8. ECOG score of 0 or 1.

9. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, IUDs, etc., during treatment and within 4 months (men) or 7 months (women) of the last use of the trial drug.

Exclusion Criteria:

1. Serum creatinine >150 µmol/L (1.7 mg/dL) or creatinine clearance <50 ml/min (Cockcroft Gault formula).

2. Hemoglobin <80g/L, or white blood cell count <2.0×109/L, or platelets <75×109/L.

3. Serum total bilirubin > 3 × upper limit of normal (ULN).

4. Serum albumin <30g/L.

5. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5×ULN.

6. international normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 x ULN.

7. Positive human immunodeficiency virus (HIV) antibody.

8. Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and positive for HBV DNA (=1×104 copies/ml or judged positive by research center criteria), or positive for hepatitis C virus (HCV) antibodies.

9. Pregnant or lactating females.

10. Received peptide receptor radionuclide therapy(PRRT) prior to randomization.

11. Received Octreotide LAR at a dose strength >30 mg/3-4 weeks (increasing dose or frequency) within 12 weeks prior to randomization.

12. Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutetium[177Lu] Oxodotreotide Injection, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of Lutetium[177Lu] Oxodotreotide Injection.

13. Received systemic antitumor therapy such as targeted therapy, immunotherapy, antitumor herbal therapy, chemotherapy within 4 weeks prior to randomization.

14. Participated in other drug clinical trials within 4 weeks prior to randomization and received treatment with the corresponding trial drug.

15. Received the following treatments within 12 weeks prior to randomization, including but not limited to surgery (except biopsy), radical radiotherapy, hepatic artery interventional embolization, cryoablation of liver metastases, or radiofrequency ablation.

16. Received external beam radiation therapy for bone metastases within 2 weeks prior to randomization

17. Toxicity of prior antitumor therapy has not returned to = grade 1 levels (except for alopecia)

18. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study.

19. Uncontrolled congestive heart failure, including baseline left ventricular ejection fraction (LVEF) <50%.

20. uncontrolled diabetes mellitus, including baseline fasting glucose > 2 x ULN or HbA1C > 6.5%.

21. Any clinically significant active infection.

22. Known other malignancies (except for those without recurrence within 5 years after adequate treatment)

23. Known hypersensitivity to Lutetium[177Lu] Oxodotreotide Injection or oxytetracycline acetate microsphere components and their excipients.

24. Known to be unsuitable for enhanced CT or MRI contrast imaging due to allergic reaction or renal insufficiency

25. Any other disease, mental status or surgical condition that is uncontrolled, may interfere with study completion (including poor compliance) or is inappropriate for the use of the investigational drug.

26. Other treatment options (e.g., chemotherapy, targeted therapy) that, in the opinion of the investigator, are more appropriate for the patient than the treatment provided in the study based on the patient's disease characteristics, i.e., the investigational drug is not the best therapeutic agent for clinical practice.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Drug:
• Lutetium[177Lu] Oxodotreotide Injection
Four administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
• Octreotide LAR
60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing
China	The first hospital of Jilin University	Changchun	Jilin
China	West China Hospital of Sichuan University	Chengdu	Sichuan
China	The First Afilliated Hospital of Fujian Medical University	Fuzhou	Fujian
China	The First Affiliated Hospital of Jinan University	Guangzhou	Guangdong
China	The First Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Affiliated Hospital of Southwest Medical University	Luzhou	Sichuan
China	Mianyang Central Hospital	Mianyang	Sichuan
China	Nanjing First Hospital	Nanjing	Jiangsu
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai
China	Zhongshan Hospital, Fudan University	Shanghai	Shanghai
China	The First Affiliated Hospital of Shanxi Medical University	Taiyuan	Shanxi
China	Tianjin Medical University Cancer Institute & Hospital	Tianjin	Tianjin
China	Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology	Wuhan	Hubei
China	Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei
China	The First Affiliated Hospital of AFMU	Xi'an	Shaanxi
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shaanxi
China	The First Affiliated Hospital of Xiamen University	Xiamen	Fujian
China	Henan Provincial People's Hospital	Zhengzhou	Henan
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Sinotau Pharmaceutical Group

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) assessed by BIRC	Progression Free Survival (PFS) was defined as the time from randomization to documented centrally assessed disease progression, as evaluated by the Blinded Independent Review Committee (BIRC), or death due to any cause. If a participant had no centrally assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).	From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Progression Free Survival (PFS) assessed by investigator	Progression Free Survival (PFS) was defined as the time from randomization to documented centrally assessed disease progression, as evaluated by the investigators, or death due to any cause. If a participant had no centrally assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).	From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Objective Response Rate (ORR)	Objective Response Rate (ORR) was calculated as the proportion of patients with tumour size reduction (sum of partial responses (PR) and complete responses (CR)) according to RECIST 1.1.	From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Duration of Response (DoR)	The Duration of Response (DoR) was defined as the time from initially meeting the criteria for response (CR or PR) until the time of progression by RECIST 1.1.	From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Time to Tumour Progression (TTP)	Time to Tumour Progression (TTP) was defined as the time from randomization to progression centrally assessed. It included patients who dropped out due to toxicity, but omitted patients who died without measured progression (censored to last follow-up date or death date).	From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Disease Control Rate (DCR)	DCR is defined as the incidence of complete response, partial response and stable disease according to RECIST v1.1.	From date of randomization until date of progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Overall Survival (OS)	20-month Progression-Free Survival was defined as the time from randomization to documented centrally assessed disease progression, as evaluated by the investigators, or death due to any cause. If a participant had no centrally assessed progression and had not died at the time of the primary endpoint analysis, the participant was regarded as censored in the context of a time to event analysis at the date of last evaluable tumor assessment. Disease progression was determined by objective tumor response status using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1).	From date of randomization until date of death from any cause up to final safety cut-off date reached,assessed up to approximately 60 months
Secondary	Change From Baseline in the EORTC QLQ-C30 Questionnaire	The Quality of Life Questionnaire C30 (QLQ-C30) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess quality of life in cancer patients. It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from "not at all" to "very much" for most items. Raw scores are linearly transformed so each score ranged a 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).	From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Change From Baseline in the EORTC Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GINET21)	The Quality of Life GI Neuroendocrine Tumor survey (QLQ GINET21) contains a total of 21 items: four single-item assessments relating to muscle and/or bone pain (MBP), body image (BI), information (INF) and sexual functioning (SX), together with 17 items organized into five proposed scales: endocrine symptoms (ED; three items), GI symptoms (GI; five items), treatment-related symptoms (TR; three items), social functioning (SF) and disease-related worries (DRW; three items). The response format of the questionnaire is a four-point Likert scale. Responses are linearly transformed to a 0-100 scale using EORTC guidelines, with higher scores reflecting more severe symptoms.	From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached,assessed up to approximately 34 months
Secondary	Number of Participants With Adverse Events	The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.	From informed consent signature through study completion reached at final safety cutoff date,assessed up to approximately 60 months